Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.93
-0.04 (-0.24%)
At close: Jul 17, 2026, 4:00 PM EDT
16.96
+0.03 (0.18%)
After-hours: Jul 17, 2026, 4:10 PM EDT

Theravance Biopharma Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Theravance Biopharma stock has a consensus rating of "Hold" and an average price target of $17.67. The average 1-year stock price forecast is 4.37% higher than the current stock price, while the lowest is $17 (+0.41%) and the highest is $19 (+12.23%).

Price Target: $17.67 (+4.37%)
Analyst Consensus: Hold

Price Target

Chart
TargetLowAverageMedianHigh
Price$17$17.67$17$19
Change+0.41%+4.37%+0.41%+12.23%

Analyst Ratings

The average analyst rating for Theravance Biopharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Chart
RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy553331
Buy000000
Hold224335
Sell000000
Strong Sell000000
Total777666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Hold
Downgrades
$17
HoldDowngrades$17+0.41%Jul 7, 2026
BTIG
BTIG
Hold
Downgrades
n/a
HoldDowngradesn/an/aJun 29, 2026
JonesTrading
JonesTrading
Hold
Downgrades
$19$17
HoldDowngrades$19$17+0.41%Jun 29, 2026
TD Cowen
TD Cowen
Hold
Reiterates
$15
HoldReiterates$15-11.40%May 8, 2026
B. Riley Securities
B. Riley Securities
Hold
Maintains
$14$17
HoldMaintains$14$17+0.41%Apr 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
84.13M
from 107.46M
Decreased by -21.71%
Revenue Next Year
97.40M
from 84.13M
Increased by 15.77%
EPS This Year
0.21
from -0.15
EPS Next Year
0.80
from 0.21
Increased by 280.95%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
55.31M51.35M57.42M64.38M107.46M84.13M
Revenue Growth
-23.03%-7.17%11.84%12.12%66.92%-21.71%
Operating Income
-237.64M-79.12M-53.65M-42.44M-3.60M16.90M
Net Income
-199.43M872.13M-55.19M-56.42M105.90M151.50M
EPS
-----0.150.21
Forward PE
-29.9629.9629.9625.8380.62
Free Cash Flow
-115.85M24.00M-12.22M-42.00M-4.12M76.60M
No. Analysts
-----3
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High93.7M
Avg84.1M
Low77.4M

Revenue Growth

Revenue Growth202620272028
High
-12.8%
Avg
-21.7%
Low
-28.0%

EPS Forecast

EPS202620272028
High0.21
Avg0.21
Low0.21

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-